Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery capabilities to identify drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Co.'s immuno-oncology pipeline consists of four clinical stage programs, COM701, which is an anti-PVRIG antibody, for the treatment of solid tumors; COM902, which is a therapeutic antibody targeting TIGIT; Bapotulimab, which is an antibody targeting ILDR2; and AZD2936, which is an anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Co.'s COM902 program. The CGEN stock yearly return is shown above.
The yearly return on the CGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|